Hospital
Thedacare Medical Center - Shawano, INC.
Thedacare Medical Center - Shawano, INC. was paid $32.77M by Medicaid between Jan 2018 and Dec 2024, across 251 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoTHEDACARE MEDICAL CENTER - SHAWANO, INC.
SHAWANO, WI 54166
SHAWANO, WI 54166
33aNPI1548260839assigned 07/28/2005
33bProvider typeCritical Access Hospital
28Total paid$32.77M
24GClaims667,792
24DCodes billed251
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#1 of 48
Median peer was paid$4.30M
This provider vs. median7.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FLETT, WILLIAM controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 79,116 | $3.34M | |
| 2019 | 81,633 | $3.74M | |
| 2020 | 80,620 | $3.66M | |
| 2021 | 103,999 | $4.50M | |
| 2022 | 110,185 | $5.38M | |
| 2023 | 114,935 | $6.66M | |
| 2024incomplete | 97,304 | $5.51M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 42,395 | 36,650 | $5.92M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 25,690 | 20,828 | $4.23M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.9% | 7,786 | 5,711 | $3.24M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.8% | 21,845 | 19,591 | $3.20M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5.7% | 7,976 | 5,351 | $1.87M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 4,833 | 4,293 | $1.47M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 4,881 | 4,363 | $1.37M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.1% | 5,536 | 4,423 | $1.01M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.1% | 4,439 | 3,950 | $695K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 1,895 | 1,269 | $512K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 1,944 | 1,575 | $495K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.4% | 4,310 | 3,112 | $470K |
239 more codes
| 41899 | Unlisted procedure, dentoalveolar structures | 1.4% | 328 | $464K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 1,771 | $415K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 1,455 | $380K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 1,197 | $374K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 41,827 | $363K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.1% | 2,259 | $354K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 11,526 | $283K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,288 | $279K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 885 | $246K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,091 | $231K |
| 87631 | <1% | 2,208 | $212K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 253 | $210K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 37,573 | $205K |
| 96367 | <1% | 994 | $189K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 640 | $149K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,128 | $147K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 367 | $146K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 6,670 | $141K |
| 12001 | <1% | 535 | $140K | |
| G0378 | Hospital observation service, per hour | <1% | 3,911 | $137K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,790 | $133K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 993 | $131K |
| 80076 | <1% | 21,826 | $123K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,674 | $105K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,566 | $96K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,837 | $88K |
| 81025 | <1% | 6,257 | $87K | |
| 80306 | <1% | 5,969 | $85K | |
| 84484 | <1% | 11,825 | $76K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 370 | $75K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 989 | $74K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,101 | $69K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,379 | $67K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 320 | $67K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,394 | $62K |
| 73564 | <1% | 1,940 | $55K | |
| 73610 | <1% | 1,978 | $51K | |
| 80061 | Lipid panel | <1% | 4,603 | $51K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,516 | $50K |
| 76801 | <1% | 535 | $50K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,414 | $49K |
| 81001 | <1% | 14,915 | $47K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,529 | $47K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 57 | $46K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 253 | $46K |
| 83690 | <1% | 8,802 | $43K | |
| 97162 | <1% | 1,288 | $43K | |
| 83880 | <1% | 3,032 | $42K | |
| 73110 | <1% | 1,230 | $41K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 783 | $41K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,704 | $39K |
| 73630 | <1% | 1,782 | $39K | |
| 96368 | <1% | 174 | $38K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 641 | $36K |
| 73030 | <1% | 1,348 | $34K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 3,993 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,625 | $34K |
| 74018 | <1% | 1,252 | $32K | |
| 93971 | <1% | 237 | $32K | |
| 83735 | <1% | 7,710 | $31K | |
| 87070 | <1% | 2,845 | $30K | |
| 76830 | Ultrasound, transvaginal | <1% | 197 | $30K |
| 83605 | <1% | 5,106 | $28K | |
| 82077 | <1% | 2,837 | $28K | |
| 72100 | <1% | 954 | $28K | |
| 87040 | <1% | 6,117 | $26K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 214 | $25K |
| 70498 | <1% | 64 | $25K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 800 | $22K |
| 85610 | <1% | 8,228 | $22K | |
| 81003 | <1% | 8,314 | $20K | |
| 73130 | <1% | 1,124 | $19K | |
| 82948 | <1% | 3,814 | $19K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 61 | $17K |
| 87650 | <1% | 489 | $16K | |
| 85380 | <1% | 2,593 | $16K | |
| 70496 | <1% | 44 | $16K | |
| 87186 | <1% | 2,713 | $15K | |
| 90715 | <1% | 527 | $15K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 697 | $15K |
| 80143 | <1% | 1,261 | $14K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 50 | $14K |
| 80179 | <1% | 1,222 | $14K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,607 | $13K |
| 12002 | <1% | 43 | $13K | |
| 86140 | <1% | 3,731 | $13K | |
| 85730 | <1% | 3,423 | $12K | |
| 80053 | Comprehensive metabolic panel | <1% | 1,194 | $11K |
| 85027 | <1% | 2,701 | $11K | |
| 87088 | <1% | 2,322 | $11K | |
| 82805 | <1% | 605 | $11K | |
| 94060 | <1% | 108 | $11K | |
| 70486 | <1% | 85 | $11K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,500 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 662 | $10K |
| 73502 | <1% | 394 | $10K | |
| 87807 | <1% | 620 | $10K | |
| 87210 | <1% | 1,558 | $9K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,626 | $9K |
| 97035 | <1% | 818 | $8K | |
| 84439 | <1% | 1,056 | $8K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,614 | $7K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 30 | $7K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 41 | $6K |
| 87634 | <1% | 94 | $6K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,486 | $6K |
| 82947 | <1% | 2,066 | $6K | |
| 82728 | <1% | 551 | $6K | |
| 71250 | <1% | 57 | $6K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 276 | $5K |
| 84702 | <1% | 355 | $5K | |
| 85651 | <1% | 1,552 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 30 | $5K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $5K |
| 86850 | <1% | 821 | $5K | |
| 85379 | <1% | 598 | $4K | |
| 87150 | <1% | 157 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 14 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 647 | $3K |
| 29125 | <1% | 60 | $3K | |
| 73080 | <1% | 112 | $3K | |
| 82570 | <1% | 799 | $3K | |
| 87081 | <1% | 525 | $3K | |
| 12011 | <1% | 19 | $3K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,167 | $3K |
| 86900 | <1% | 995 | $3K | |
| 76770 | <1% | 15 | $3K | |
| 88720 | <1% | 251 | $3K | |
| 73140 | <1% | 113 | $3K | |
| 93017 | <1% | 15 | $3K | |
| 76642 | <1% | 13 | $2K | |
| 82962 | <1% | 1,398 | $2K | |
| 86901 | <1% | 995 | $2K | |
| 93225 | <1% | 28 | $2K | |
| 97161 | <1% | 53 | $2K | |
| 85652 | <1% | 900 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 15 | $2K |
| 82550 | <1% | 439 | $2K | |
| 86618 | <1% | 99 | $2K | |
| 83550 | <1% | 297 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 28 | $2K |
| 36592 | <1% | 1,069 | $1K | |
| 94729 | <1% | 93 | $1K | |
| 87340 | <1% | 177 | $1K | |
| 87486 | <1% | 50 | $1K | |
| 83540 | <1% | 334 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 51 | $1K |
| 87581 | <1% | 50 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,329 | $1K |
| 82043 | <1% | 226 | $1K | |
| 82607 | <1% | 100 | $936.78 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 28 | $929.58 |
| 82565 | <1% | 235 | $853.47 | |
| 97166 | <1% | 38 | $840.79 | |
| 86780 | <1% | 82 | $741.95 | |
| 84703 | <1% | 100 | $692.48 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 542 | $669.57 |
| 86703 | <1% | 39 | $585.97 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,388 | $515.98 |
| 73590 | <1% | 56 | $514.93 | |
| 85014 | <1% | 218 | $494.43 | |
| 93226 | <1% | 12 | $480.66 | |
| 82150 | <1% | 94 | $479.46 | |
| 74019 | <1% | 43 | $458.85 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,405 | $440.19 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,436 | $428.51 |
| 83655 | <1% | 28 | $419.11 | |
| 84100 | <1% | 121 | $415.01 | |
| 96376 | <1% | 3,623 | $385.14 | |
| 97163 | <1% | 12 | $380.99 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 8,223 | $351.38 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 566 | $349.77 |
| 85018 | <1% | 204 | $330.49 | |
| 72040 | <1% | 13 | $304.84 | |
| 51702 | <1% | 18 | $301.05 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,227 | $250.25 |
| 80055 | <1% | 12 | $229.31 | |
| 71101 | <1% | 41 | $217.69 | |
| 82274 | <1% | 28 | $207.70 | |
| 94726 | <1% | 27 | $206.41 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,721 | $204.65 |
| 0100U | <1% | 15 | $171.01 | |
| 84460 | <1% | 30 | $153.46 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,689 | $142.46 |
| 82553 | <1% | 36 | $138.56 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,574 | $137.26 |
| 84550 | <1% | 28 | $129.33 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,264 | $121.58 |
| 87147 | <1% | 29 | $114.22 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 283 | $105.57 |
| 88738 | <1% | 16 | $92.71 | |
| 82950 | <1% | 14 | $86.43 | |
| 84145 | <1% | 13 | $84.85 | |
| 82272 | <1% | 28 | $83.96 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,171 | $78.81 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 899 | $77.12 |
| 36591 | <1% | 25 | $69.57 | |
| 82010 | <1% | 12 | $67.77 | |
| 87077 | <1% | 15 | $66.69 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,874 | $64.36 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,416 | $46.07 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,215 | $34.78 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 9,549 | $32.55 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,472 | $29.44 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 383 | $27.65 |
| 36416 | <1% | 21 | $27.13 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 718 | $24.46 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,003 | $21.79 |
| J3490 | Unclassified drugs | <1% | 692 | $15.87 |
| A9270 | Non-covered item or service | <1% | 1,719 | $14.47 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 474 | $14.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 434 | $13.55 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 978 | $7.49 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 13 | $6.56 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 160 | $6.14 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 100 | $3.56 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 114 | $1.59 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 33 | $0.93 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 121 | $0.91 |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 365 | $0.59 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 478 | $0.46 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 2,603 | $0.01 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 120 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 414 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 105 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 182 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 33 | $0.00 |
| 88304 | 0% | 31 | $0.00 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | 0% | 27 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 35 | $0.00 |
| 94760 | 0% | 178 | $0.00 | |
| J2002 | Injection, lidocaine hcl in 5% dextrose, 1 mg | 0% | 15 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 14 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 30 | $0.00 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 0% | 109 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 42 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 108 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 70 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFLETT, WILLIAM (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.